Sign in

You're signed outSign in or to get full access.

Suzanne Campion

Director at Ardent Health
Board

About Suzanne Campion

Independent director of Ardent Health Partners, Inc. (ARDT) since December 2021; age 63 as of April 1, 2025. She brings 25+ years in finance and operating roles across Citigroup, Front Barnett Associates, J.P. Morgan & Co., and Bankers Trust, plus leadership in executive search and nonprofit advisory. Education: B.A. in Economics (St. Olaf College) and MBA (Kellogg School of Management, Northwestern University). Board concluded she qualifies as an independent director under NYSE rules notwithstanding affiliations with EGI/Chai Trust .

Past Roles

OrganizationRoleTenureCommittees/Impact
Doran Leadership PartnersManaging Director & COO; later AdvisorBuilt and led operations through April 2022; Advisor until January 2024Helped structure and build the firm; operations and governance leadership
NextLevelNPOCo‑founder; later AdvisorCo‑founded 2013; Advisor from 2019; resigned early 2024Operational, financial and strategic advisory to nonprofits
Citigroup; Front Barnett Associates; J.P. Morgan & Co.; Bankers Trust CompanyFinance/operations/client advisory/investments/HRAugust 1988–September 2012Broad finance, strategy, and human capital experience across investment firms

External Roles

OrganizationRoleTenureCommittees/Impact
Chai Trust Company, LLC (corporate trustee for Zell family trusts)Director; Chair, Governance Committee; Chair, Distribution & Beneficiary Relations CommitteeSince April 2019Governance leadership; fiduciary oversight aligned with controlling shareholder’s trust structures
KIPP Chicago Public Charter School BoardBoard MemberSince January 2014Education nonprofit governance
Ann & Robert H. Lurie Children’s Hospital of ChicagoFounder’s Board MemberSince January 2005Philanthropic support and community engagement
Frank S. Ortiz Dog Park (Santa Fe)Board MemberJoined after moving to Santa Fe in 2023Community parks oversight

Board Governance

  • Committee assignments: Compensation Committee (member; committee chaired by Ellen Havdala; 9 meetings in 2024) and Nominating & Corporate Governance Committee (member; committee chaired by Peter Bynoe; 5 meetings in 2024) .
  • Attendance: Each director attended at least 75% of Board and applicable committee meetings in 2024 (Board met 6 times) .
  • Independence: ARDT is a controlled company under NYSE rules (EGI-AM controls >50% voting power), but Board determined Ms. Campion is independent despite EGI/Chai Trust affiliations and nomination under the Nomination Agreement; audit committee independence maintained per NYSE requirements .
  • Nomination rights: EGI-AM can nominate a majority of directors and designate the Chair while owning ≥50% voting power; Ms. Campion was designated by EGI-AM .
  • Executive sessions: Non-employee and independent directors meet in executive session regularly, at least annually, without management present .

Fixed Compensation (Director)

ComponentAmount/Terms2024 Actual (Campion)
Annual cash retainer (non‑employee director)$100,000; paid quarterly, prorated for partial year $96,250 fees earned in cash
Committee retainers (member)Audit $15,000; Compensation $10,000; Nominating $7,500; Quality $10,000; Chair premiums vary by committee Included in total fees earned; specific mix not separately disclosed
Annual Director RSUs (2024 Program)$185,000 grant date value; vest generally over 12 months; 2024 grants vest March 31, 2025; accelerated vest on Change in Control Included in stock awards total
Special Director RSUs (December 2024)Additional RSUs issued for retention; vest one‑third on Dec 12, 2025/2026/2027; similar accelerated vesting/forfeiture rules Included in stock awards total
2024 Stock awards (aggregate grant‑date fair value)$365,235

Performance Compensation (Director)

ElementMetricsVesting/Terms
Director equity awardsNo performance metrics; time‑based RSUs (Annual & Special Director RSUs)Annual Director RSUs vest March 31, 2025 (for 2024 grants); Special Director RSUs vest in three equal tranches on Dec 12, 2025/2026/2027

Directors are not eligible for bonus/equity awards tied to corporate performance metrics; compensation is cash retainers plus time‑vesting RSUs .

Other Directorships & Interlocks

Company/EntityTypeRelationship/InterlockNotes
Chai Trust Company, LLCCorporate trusteeMs. Campion serves on board and chairs governance committees; Chai Trust is corporate trustee for Zell family trusts affiliated with EGI, ARDT’s controlling stockholder Potential information flow/interlock with controlling shareholder; Board assessed and affirmed independence
EGI-AM Nomination AgreementGovernance agreementEGI-AM holds right to nominate majority of ARDT directors; Ms. Campion designated by EGI-AM Controlled company governance structure

Expertise & Qualifications

  • Finance and operations across leading investment firms; strategic and human capital expertise spans client advisory, investments, analysis, and HR (1988–2012) .
  • Executive search/Ops leadership at Doran Leadership Partners; nonprofit advisory (NextLevelNPO) .
  • Strong governance credentials via Chai Trust (committee chair roles) and multiple nonprofit boards .
  • Education: Economics (St. Olaf), MBA (Kellogg, Northwestern) .

Equity Ownership

MetricValue
Total beneficial ownership (shares)20,275; includes 11,562 RSUs vesting March 31, 2025
Percent of class<1%
RSUs outstanding (as of Dec 31, 2024)22,355 RSUs (Annual + Special Director RSUs)
Director ownership guideline5× annual cash retainer; non‑employee directors must hold 50% of shares acquired until guideline met
Guideline complianceAs of Dec 31, 2024, all non‑employee directors except Messrs. Sotir and Sen met the guideline (Campion compliant)
Vesting schedule notesAnnual Director RSUs: vest March 31, 2025 for 2024 grants; Special Director RSUs: vest Dec 12, 2025/2026/2027

Governance Assessment

  • Positives: Independent under NYSE rules despite EGI/Chai Trust affiliations; multi‑committee service (Compensation and Nominating) indicates engagement; attended ≥75% of meetings; director ownership guideline compliance supports alignment .
  • Structural risks: Controlled company status reduces some NYSE governance requirements (no need for majority independent board or independent nominating function); EGI‑AM nomination rights; affiliations with controlling shareholder (Chai Trust) present potential perception risk; Board disclosed related agreements with EGI/EGI‑AM and Ventas and concluded independence not impaired .
  • Compensation signals: Cash/equity mix consistent with market; issuance of Special Director RSUs for retention indicates attention to director continuity post‑IPO .
  • RED FLAGS to monitor: Controlled company governance exemptions; director designation by controlling holder; ongoing related‑party arrangements disclosed (EGI/EGI‑AM services; Ventas leases) though Board asserts objective oversight by independent directors .

Committee Assignments (Detail)

CommitteeRole2024 Meetings
Compensation CommitteeMember (Chair: Ellen Havdala)9
Nominating & Corporate Governance CommitteeMember (Chair: Peter Bynoe)5

Director Compensation (Detail)

YearFees Earned (Cash)Stock Awards (Grant‑Date Fair Value)Total
2024$96,250 $365,235 $461,485

Program terms: $100,000 annual cash retainer; committee member fees (Audit $15k; Compensation $10k; Nominating $7.5k; Quality $10k) and chair premiums; Annual Director RSUs of $185,000; Special Director RSUs in December 2024 for retention with three‑year time‑based vesting .

Related‑Party & Independence Disclosures

  • Controlled company: EGI‑AM controls >50% voting power; retains nomination rights for majority of directors and Board Chair .
  • Independence determination: Board assessed EGI/EGI‑AM and Ventas relationships and payments under services and lease agreements, and affirmed independence of designees including Ms. Campion .
  • Nomination Agreement: Ms. Campion designated by EGI‑AM .

Insider Trades

  • The proxy discloses beneficial ownership and director compensation; it does not list Form 4 transaction details for directors. No additional insider trading transactions are referenced in this document; refer to current Form 4 filings for real‑time updates .

Notes on Attendance and Board Structure

  • Board met six times in 2024; each director attended ≥75% of applicable meetings .
  • Executive sessions are held regularly without management present; independent directors meet at least annually .
  • Current Chair of the Board: Mark Sotir; CEO also serves as director (separate roles) .